Novel Use of Pepinemab and Nivolumab and FOLFIRINOX Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma (Phase Ib/II)

Pancreatic Cancer
David Linehan, MD
University of Rochester


Dr. Linehan’s trial is examining the use of a dual immunotherapy approach in combination with standard chemotherapy to treat inoperable and locally advanced pancreatic ductal cancer (PDAC). The dual immunotherapy drugs, nivolumab and pepinemab, will activate the immune system to fight against the pancreatic tumors thereby enhancing the effectiveness of the chemotherapy folfirinox in targeting and eradicating the tumor cells. If successful, this trial will result in a new, more effective treatment approach for patients diagnosed with PDAC.